Clinical Trials List
2022-12-09 - 2029-06-30
Phase III
Not yet recruiting3
ICD-10B96.20
Unspecified Escherichia coli [E. coli] as the cause of diseases classified elsewhere
ICD-10B96.21
Shiga toxin-producing Escherichia coli [E. coli] (STEC) O157 as the cause of diseases classified elsewhere
ICD-10B96.22
Other specified Shiga toxin-producing Escherichia coli [E. coli] (STEC) as the cause of diseases classified elsewhere
ICD-10B96.23
Unspecified Shiga toxin-producing Escherichia coli [E. coli] (STEC) as the cause of diseases classified elsewhere
ICD-10B96.29
Other Escherichia coli [E. coli] as the cause of diseases classified elsewhere
ICD-9041.4
Escherichia coli﹝E.coli﹞infections of unspeciied site
-
Trial Applicant
Pharmaceutical Research Associates Taiwan Inc.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- Shih-Tsung Huang Division of Urology
- 鄭鈞文 Division of Infectious Disease
- Ya-Chung Tian Division of Nephrology
- 李怡蓉 Division of Nephrology
- 陳怡文 Division of Endocrinology
- 黃信介 Division of Urology
- Po-Yan Huang Division of Infectious Disease
- Nan-Yu Chen Division of Infectious Disease
- 楊皇煜 Division of Nephrology
- Yu-Yao Huang Division of Endocrinology
- 許毓昭 Division of Urology
- Peng-Hao Chang Division of Infectious Disease
- 尤俊成 Division of Nephrology
- 吳欣旭 Division of Nephrology
- Jau-Yuan Chen Division of Family Medicine
- See-Tong Pang Division of Urology
- Ting-Shu Wu Division of Infectious Disease
- Ting Yi Su Division of Infectious Disease
- HSIANG-HAO HSU Division of Nephrology
- Yingren Chen Division of Geriatrics
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 黃資雅 Division of Family Medicine
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- 孫健耀 未分科
- 吳至行 未分科
- Nan-Yao Lee 未分科
- 王峻令 未分科
- Ying-Chien Ou 未分科
- Wei-Hung Lin 未分科
- 薛伶珊 未分科
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
500 participants
-
Global
19800 participants
